Nimodipine-Induced Blood Pressure Changes Can Predict Delayed Cerebral Ischemia
- PMID: 31736865
- PMCID: PMC6834786
- DOI: 10.3389/fneur.2019.01161
Nimodipine-Induced Blood Pressure Changes Can Predict Delayed Cerebral Ischemia
Abstract
Background: Early diagnosis of delayed cerebral ischemia (DCI) in patients after aneurysmal subarachnoid hemorrhage (aSAH) still poses a leading problem in neurointensive care. The aim of this study was to analyze the effect of oral Nimodipine administration on systemic blood pressure in patients with evolving DCI compared to patients without DCI. Methods: Systolic (SBP), mean (MAP), and diastolic (DBP) blood pressures were analyzed at the time of Nimodipine administration and additionally 30, 60, and 120 min thereafter on days 1, 3, and 5 after aSAH. Additionally, the 24 h period preceding DCI and in patients without DCI day 10 after aSAH were analyzed. Statistical analysis was performed for SBP, MAP and DBP at time of Nimodipine administration and for the maximal drop in blood pressure after Nimodipine administration. Results: Thirty patients with aSAH were retrospectively analyzed with 17 patients developing DCI ("DCI") and 13 patients who did not ("Non-DCI"). DCI patients showed a more pronounced rise in MAP and DBP over the examined time period as well as a higher decrease in SBP following Nimodipine administration. A fall of 18 mmHg in SBP after Nimodipine administration showed a sensitivity of 82.4% and specificity of 92.3% for occurrence of DCI. Conclusion: An increase of MAP and DBP after aSAH and a heightened sensitivity to Nimodipine administrations may serve as additional biomarkers for early detection of evolving DCI.
Keywords: Nimodipine; blood pressure variability; cerebral infarction; cerebral perfusion; cerebral vasospasm; delayed cerebral ischemia; hypertension.
Copyright © 2019 Fischer, Goldberg, Vulcu, Wagner, Schöni, Söll, Hänggi, Schefold, Fung, Beck, Raabe and Z'Graggen.
Figures

Similar articles
-
Does Nimodipine Interruption due to High Catecholamine Doses Lead to a Greater Incidence of Delayed Cerebral Ischemia in the Setting of Aneurysmal Subarachnoid Hemorrhage?World Neurosurg. 2019 Dec;132:e834-e840. doi: 10.1016/j.wneu.2019.08.001. Epub 2019 Aug 9. World Neurosurg. 2019. PMID: 31404696
-
Risks of nimodipine dose reduction during the high-risk period for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.Neurosurg Rev. 2024 Jan 9;47(1):37. doi: 10.1007/s10143-023-02273-0. Neurosurg Rev. 2024. PMID: 38191859
-
Early whole-brain CT perfusion for detection of patients at risk for delayed cerebral ischemia after subarachnoid hemorrhage.J Neurosurg. 2016 Jul;125(1):128-36. doi: 10.3171/2015.6.JNS15720. Epub 2015 Dec 18. J Neurosurg. 2016. PMID: 26684786
-
Vasospasm on transcranial Doppler is predictive of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.J Neurosurg. 2016 May;124(5):1257-64. doi: 10.3171/2015.4.JNS15428. Epub 2015 Oct 23. J Neurosurg. 2016. PMID: 26495942 Review.
-
Investigational drugs for vasospasm after subarachnoid hemorrhage.Expert Opin Investig Drugs. 2018 Apr;27(4):313-324. doi: 10.1080/13543784.2018.1460353. Epub 2018 Apr 6. Expert Opin Investig Drugs. 2018. PMID: 29600883 Review.
Cited by
-
Safety of Modified Nimodipine Dosing in Aneurysmal Subarachnoid Hemorrhage.World Neurosurg. 2022 Feb;158:e501-e508. doi: 10.1016/j.wneu.2021.11.016. Epub 2021 Nov 11. World Neurosurg. 2022. PMID: 34775086 Free PMC article.
-
Sex-Related Differences in Mortality, Delayed Cerebral Ischemia, and Functional Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.J Clin Med. 2024 May 9;13(10):2781. doi: 10.3390/jcm13102781. J Clin Med. 2024. PMID: 38792323 Free PMC article. Review.
-
Devastating delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.Front Neurol. 2022 Oct 13;13:1016111. doi: 10.3389/fneur.2022.1016111. eCollection 2022. Front Neurol. 2022. PMID: 36313513 Free PMC article.
References
-
- Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al. . Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter Phase IIa study. J Neurosurg. (2005) 103:9–17. 10.3171/jns.2005.103.1.0009 - DOI - PubMed